Abstract Number: PB0686
Meeting: ISTH 2021 Congress
Background: Hemophilia is a rare bleeding disorder that requires treatment for life. While therapeutic options were limited in the past, multiple new hemophilia therapies have reached marketing authorization in recent years.
Aims: The aim of this evaluation is to analyze specific aspects of data collected in the German Hemophilia Registry (Deutsches Hämophilieregister, dhr) for the impact of these new therapies on the treatment of German hemophilia patients.
Methods: To identify changes in total factor consumption or shifts in product class preferences, the per-capita factor consumption of relevant patient groups was calculated and correlated with the market access of novel products for the past decade in Germany.
Results: Preliminary results suggest an interesting shift in selected aspects of hemophilia treatment in Germany due to the availability of new therapeutic options.
Conclusions: Data collected in the German hemophilia registry support the contemporary investigation of real time data to elaborate on patient-orientated supply.
To cite this abstract in AMA style:Duda H, Haschberger B, Hesse J, Windecker H, Hilger A, Keipert C. Do New Therapies alter the Treatment of Hemophilia Patients? [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/do-new-therapies-alter-the-treatment-of-hemophilia-patients/. Accessed September 23, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/do-new-therapies-alter-the-treatment-of-hemophilia-patients/